{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:02:17Z","timestamp":1790762537453,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s13139-026-01015-6","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T07:29:23Z","timestamp":1776238163000},"page":"552-565","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic Impact of Liver Metastases on [177Lu]Lu-PSMA Therapy Outcomes in Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1007","volume":"60","author":[{"given":"Amirreza","family":"Shamshirgaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hadi","family":"Samadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"Sahafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Aboutalebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hessamoddin","family":"Roustaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Shafiei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Aryana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atena","family":"Aghaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somaye","family":"Barashki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6196-6982","authenticated-orcid":false,"given":"Sara","family":"Harsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emran","family":"Askari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"1015_CR1","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s11864-024-01215-2","volume":"25","author":"T Kulasegaran","year":"2024","unstructured":"Kulasegaran T, Oliveira N. Metastatic castration-resistant prostate cancer: advances in treatment and symptom management. Curr Treat Options Oncol. 2024;25:914\u201331.","journal-title":"Curr Treat Options Oncol"},{"key":"1015_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.clgc.2019.03.020","volume":"17","author":"J Budnik","year":"2019","unstructured":"Budnik J, Suri J, Bates JE, Bylund KC, Milano MT. Prognostic significance of sites of visceral metastatic disease in prostate cancer: a population-based study of 12,180 patients. Clin Genitourin Cancer. 2019;17:260\u20137.","journal-title":"Clin Genitourin Cancer"},{"key":"1015_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-022-00469-z","volume":"22","author":"K Ruchalski","year":"2022","unstructured":"Ruchalski K, Kim HJ, Douek M, Raman S, Patel M, Sai V, et al. Pretreatment visceral metastases in castration resistant metastatic prostate cancer: role in prediction versus actual site of disease progression. Cancer Imaging. 2022;22:34.","journal-title":"Cancer Imaging"},{"key":"1015_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4103\/ua.ua_102_22","volume":"15","author":"SS Sarangi","year":"2023","unstructured":"Sarangi SS, Singh V, Bhirud DP. Cutaneous metastasis of castration-resistant prostate cancer: a rare case report and review of literature. Urol Ann. 2023;15:98\u2013100.","journal-title":"Urol Ann"},{"key":"1015_CR5","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2020.1159","volume":"14","author":"M Gosein","year":"2020","unstructured":"Gosein M, Mohammed L, Chan A, Sinanan A, Banfield R, Maharaj P, et al. A pictorial review of the less commonly encountered patterns of metastatic prostate carcinoma. Ecancermedicalscience. 2020;14:1159.","journal-title":"Ecancermedicalscience"},{"key":"1015_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.eururo.2013.09.024","volume":"65","author":"GR Pond","year":"2014","unstructured":"Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014;65:3\u20136.","journal-title":"Eur Urol"},{"key":"1015_CR7","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","volume":"34","author":"S Halabi","year":"2016","unstructured":"Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34:1652\u20139.","journal-title":"J Clin Oncol"},{"key":"1015_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1002\/pros.23492","volume":"78","author":"J Shou","year":"2018","unstructured":"Shou J, Zhang Q, Wang S, Zhang D. The prognosis of different distant metastases pattern in prostate cancer: a population based retrospective study. Prostate. 2018;78:491\u20137.","journal-title":"Prostate"},{"key":"1015_CR9","doi-asserted-by":"publisher","first-page":"160.e1","DOI":"10.1016\/j.urolonc.2024.01.032","volume":"42","author":"P Zhang","year":"2024","unstructured":"Zhang P, Chen T, Yang M. Comparative analysis of prognosis and gene expression in prostate cancer patients with site-specific visceral metastases. Urol Oncol. 2024;42:160.e1-e10.","journal-title":"Urol Oncol"},{"key":"1015_CR10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804.","journal-title":"Lancet"},{"key":"1015_CR11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","volume":"75","author":"MM Heck","year":"2019","unstructured":"Heck MM, Tauber R, Schwaiger S, Retz M, D\u2019Alessandria C, Maurer T, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2019;75:920\u20136.","journal-title":"Eur Urol"},{"key":"1015_CR12","doi-asserted-by":"publisher","first-page":"757","DOI":"10.2967\/jnumed.124.269215","volume":"66","author":"A Al-Ibraheem","year":"2025","unstructured":"Al-Ibraheem A, Scott AM, Abdlkadir AS, Vrachimis A, Lamoureux F, Trujillo PB, et al. Consensus nomenclature for radionuclide therapy: initial recommendations from nuclear medicine global initiative. J Nucl Med. 2025;66:757\u201363.","journal-title":"J Nucl Med"},{"key":"1015_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"1015_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3390\/cancers14030557","volume":"14","author":"J Baumgarten","year":"2022","unstructured":"Baumgarten J, Groener D, Nguyen Ngoc C, Mader N, Chaurasia M, Davis K, et al. Safety and efficacy of 177Lutetium-PSMA-617 radioligand therapy shortly after failing 223Radium-dichloride. Cancers. 2022;14:557.","journal-title":"Cancers"},{"key":"1015_CR15","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1007\/s00259-020-05082-5","volume":"48","author":"S Rasul","year":"2021","unstructured":"Rasul S, Hartenbach M, Wollenweber T, Kretschmer-Chott E, Grubm\u00fcller B, Kramer G, et al. Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:1650\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1015_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/RLU.0000000000002833","volume":"45","author":"MP Yadav","year":"2020","unstructured":"Yadav MP, Ballal S, Bal C, Sahoo RK, Damle NA, Tripathi M, et al. Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients. Clin Nucl Med. 2020;45:19\u201331.","journal-title":"Clin Nucl Med"},{"key":"1015_CR17","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1097\/RLU.0000000000003307","volume":"45","author":"S Satapathy","year":"2020","unstructured":"Satapathy S, Mittal BR, Sood A. Visceral metastases as predictors of response and survival outcomes in patients of castration-resistant prostate cancer treated with 177Lu-labeled prostate-specific membrane antigen radioligand therapy: a systematic review and meta-analysis. Clin Nucl Med. 2020;45:935\u201342.","journal-title":"Clin Nucl Med"},{"key":"1015_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Sch\u00e4fers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85.","journal-title":"J Nucl Med"},{"key":"1015_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2025","unstructured":"Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol. 2025;22:26\u201345.","journal-title":"Nat Rev Urol"},{"key":"1015_CR20","first-page":"1932","volume":"65","author":"M Muniz","year":"2024","unstructured":"Muniz M, Sartor O, Orme JJ, Koch RM, Rosenow HR, Mahmoud AM, et al. Outcomes for patients with metastatic castration-resistant prostate cancer and liver metastasis receiving [(177)Lu]Lu-PSMA-617. J Nucl Med. 2024;65:1932\u20138.","journal-title":"J Nucl Med"},{"key":"1015_CR21","first-page":"239","volume":"41","author":"S Zarehparvar Moghadam","year":"2022","unstructured":"Zarehparvar Moghadam S, Askari E, Divband G, Shakeri S, Aryana K. Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with (177)Lu-PSMA-617: a single center study. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022;41:239\u201346.","journal-title":"Rev Esp Med Nucl Imagen Mol (Engl Ed)"},{"key":"1015_CR22","unstructured":"US Department of Health and Human Services. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. 2017 [Internet]. 2020."},{"key":"1015_CR23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649\u201355.","journal-title":"Am J Clin Oncol"},{"key":"1015_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-Ligand PET\/CT. J Nucl Med. 2018;59:469.","journal-title":"J Nucl Med"},{"key":"1015_CR25","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34:1402\u201318.","journal-title":"J Clin Oncol"},{"key":"1015_CR26","first-page":"1","volume":"8","author":"B Albalooshi","year":"2020","unstructured":"Albalooshi B, Al Sharhan M, Bagheri F, Miyanath S, Ray B, Muhasin M, et al. Direct comparison of (99m)Tc-PSMA SPECT\/CT and (68)Ga-PSMA PET\/CT in patients with prostate cancer. Asia Ocean J Nucl Med Biol. 2020;8:1\u20137.","journal-title":"Asia Ocean J Nucl Med Biol"},{"key":"1015_CR27","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","volume":"50","author":"C Kratochwil","year":"2023","unstructured":"Kratochwil C, Fendler WP, Eiber M, Hofman MS, Emmett L, Calais J, et al. Joint EANM\/SNMMI procedure guideline for the use of (177)Lu-labeled PSMA-targeted radioligand-therapy ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2023;50:2830\u201345.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1015_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-05341-2","volume":"42","author":"M Wenzel","year":"2024","unstructured":"Wenzel M, Hoeh B, Humke C, Koll F, Cano Garcia C, Siech C, et al. Influence of metastatic sites and burden on oncological outcomes in patients progressing to metastatic castration resistant prostate cancer. World J Urol. 2024;42:615.","journal-title":"World J Urol"},{"key":"1015_CR29","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s00259-023-06119-1","volume":"50","author":"N Mader","year":"2023","unstructured":"Mader N, Nguyen Ngoc C, Kirkg\u00f6ze B, Baumgarten J, Groener D, Klimek K, et al. Extended therapy with [(177)Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2023;50:1811\u201321.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1015_CR30","first-page":"10","volume":"11","author":"MH Samadi","year":"2022","unstructured":"Samadi MH, Forouzanian S, Sahafi P, Ghabaei FJ, Aghaee A. Sudden Diffuse Hepatic Metastases After First 177Lu-PSMA Cycle in Bone Predominant mCRPC Patient. Clin Nucl Med. 2022;11:10\u201397.","journal-title":"Clin Nucl Med"},{"key":"1015_CR31","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, et al. Nomograms to predict outcomes after (177)Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22:1115\u201325.","journal-title":"Lancet Oncol"},{"key":"1015_CR32","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00259-021-05525-7","volume":"49","author":"F Khreish","year":"2022","unstructured":"Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, et al. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2022;49:1075\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1015_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13030569","volume":"13","author":"E Kalender","year":"2025","unstructured":"Kalender E, Ekinci E, Elbo\u011fa U, \u015eahin E. Efficacy of 177Lu-PSMA-617 therapy in mCRPC patients with liver metastases: insights into survival outcomes and predictors of response. Biomedicines. 2025;13:569.","journal-title":"Biomedicines"},{"key":"1015_CR34","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1097\/RLU.0000000000005046","volume":"49","author":"E Askari","year":"2024","unstructured":"Askari E, Aryana K, Jafarian AH, Bari A, Barashki S. Quadruplet therapy in de novo high-volume mixed neuroendocrine prostate cancer using 177Lu-PSMA: a case report. Clin Nucl Med. 2024;49:e120\u20132.","journal-title":"Clin Nucl Med"},{"key":"1015_CR35","doi-asserted-by":"publisher","first-page":"4841","DOI":"10.7150\/thno.35759","volume":"9","author":"K Kessel","year":"2019","unstructured":"Kessel K, Seifert R, Sch\u00e4fers M, Weckesser M, Schlack K, Boegemann M, et al. Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617. Theranostics. 2019;9:4841\u20138.","journal-title":"Theranostics"},{"key":"1015_CR36","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1007\/s00259-022-05853-2","volume":"49","author":"PE Hartrampf","year":"2022","unstructured":"Hartrampf PE, Seitz AK, Weinzierl FX, Serfling SE, Schirbel A, Rowe SP, et al. Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [(177)Lu]Lu-PSMA I&T during long-term follow-up. Eur J Nucl Med Mol Imaging. 2022;49:4262\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1015_CR37","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","volume":"47","author":"F Khreish","year":"2020","unstructured":"Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, et al. (225)Ac-PSMA-617\/(177)Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47:721\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1015_CR38","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024;25:175\u201383.","journal-title":"Lancet Oncol"},{"key":"1015_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s13139-024-00891-0","volume":"59","author":"AS Abdlkadir","year":"2025","unstructured":"Abdlkadir AS, Rosar F, Jalilian A, Moghrabi S, Al-Balooshi B, Rabei O, et al. Harnessing terbium radioisotopes for clinical advancements: a systematic review. Nucl Med Mol Imaging. 2025;59:50\u201361.","journal-title":"Nucl Med Mol Imaging"},{"key":"1015_CR40","volume":"11","author":"D Groener","year":"2021","unstructured":"Groener D, Nguyen CT, Baumgarten J, Bockisch B, Davis K, Happel C, et al. Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2021;11:61.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1015_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12301-021-00170-w","volume":"27","author":"S Ozdemir","year":"2021","unstructured":"Ozdemir S, Ersay AR, Koc Ozturk F, Ozdemir BS. Predictive value of standard serum markers for bone metastases in prostate cancer. Afr J Urol. 2021;27:69.","journal-title":"Afr J Urol"},{"key":"1015_CR42","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3109\/0284186X.2015.1043026","volume":"54","author":"F Petrelli","year":"2015","unstructured":"Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. Acta Oncol. 2015;54:961\u201370.","journal-title":"Acta Oncol"},{"key":"1015_CR43","doi-asserted-by":"publisher","first-page":"e1006225","DOI":"10.1371\/journal.pgen.1006225","volume":"12","author":"A Sveen","year":"2016","unstructured":"Sveen A, L\u00f8es IM, Alagaratnam S, Nilsen G, H\u00f8land M, Lingj\u00e6rde OC, et al. Intra-patient inter-metastatic genetic heterogeneity in colorectal cancer as a key determinant of survival after curative liver resection. PLoS Genet. 2016;12:e1006225.","journal-title":"PLoS Genet"},{"key":"1015_CR44","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jclinepi.2004.10.016","volume":"58","author":"BR Shah","year":"2005","unstructured":"Shah BR, Laupacis A, Hux JE, Austin PC. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol. 2005;58:550\u20139.","journal-title":"J Clin Epidemiol"},{"key":"1015_CR45","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","volume":"69","author":"MC Elze","year":"2017","unstructured":"Elze MC, Gregson J, Baber U, Williamson E, Sartori S, Mehran R, et al. Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies. J Am Coll Cardiol. 2017;69:345\u201357.","journal-title":"J Am Coll Cardiol"}],"container-title":["Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-026-01015-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13139-026-01015-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13139-026-01015-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:16:36Z","timestamp":1790759796000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13139-026-01015-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1015"],"URL":"https:\/\/doi.org\/10.1007\/s13139-026-01015-6","relation":{},"ISSN":["1869-3474","1869-3482"],"issn-type":[{"value":"1869-3474","type":"print"},{"value":"1869-3482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by institutional review board (IR.MUMS.fm.REC.1396.414). All patients signed the written informed consent prior to treatment.","order":1,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Participation","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical Trial Number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients agree to publication.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Declaration of Generative AI in Scientific Writing","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Preprint Sharing","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amirreza Shamshirgaran, Mohammad Hadi Samadi, Pegah Sahafi, Fatemeh Aboutalebi, Hessamoddin Roustaei, Susan Shafiei, Kamran Aryana, Atena Aghaee, Somaye Barashki, Sara Harsini, and Emran Askari declare that they have no conflict of interest.","order":7,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}